Test icaritin vs huachansu for advanced liver cancer with poor health
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 3 trial compares two medicines—icaritin soft capsules versus huachansu tablets—as first treatment for unresectable hepatocellular carcinoma (HCC) that has “poor prognosis” blood test markers. It aims to see which option works better and is safer for people who can’t use standard first-line treatments or don’t want them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older, and you have liver cancer called HCC confirmed by scans or tissue testing
- Your liver cancer cannot be removed with surgery, and you haven’t had any first-line “systemic” cancer treatment for HCC before
- Your blood “biomarker score” is at least 2 based on AFP, TNF-α, and IFN-γ results
- Your liver and kidney blood tests are within limits (including Child-Pugh score 7 or less)
- You can swallow the study pills and you’re well enough to do daily activities (ECOG 0–1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
This study is testing whether combining targeted therapy with immunotherapy can help people with advanced liver cancer that cannot be surgically removed. The goal is to see if this combination treatment is safe and effective.
This trial studies HAIC, a type of targeted treatment delivered into the liver, for advanced hepatocellular carcinoma (liver cancer) that has already been treated with immune and anti-blood-vessel therapies. It aims to see whether HAIC can help control the cancer safely after those earlier treatments.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial tests whether adding an oral herbal medicine (Icaritin) to standard combination therapy (TACE, immunotherapy, and targeted therapy) works better than the standard combination alone for advanced liver cancer that cannot be removed with surgery. It may be a good option if you haven't had whole-body cancer treatment before and your liver is still working well.
This trial tests combining a natural compound (Icaritin) with standard chemotherapy (mFOLFOX) after liver cancer surgery to lower the chance of the cancer coming back. It is for patients whose cancer had certain high-risk features, like a large tumor or cancer in blood vessels.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.